Non-Invasive Chromosomal Evaluation of Trisomy Study (NCT02201862) | Clinical Trial Compass
CompletedNot Applicable
Non-Invasive Chromosomal Evaluation of Trisomy Study
United States2,000 participantsStarted 2014-04
Plain-language summary
This study is being conducted to provide clinically annotated samples to support continued improvements in the Ariosa Test content, methodology, specimen processing and quality control.
Who can participate
Age range18 Years – 60 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. Subject is at least 18 years old and can provide informed consent;
* 2\. Subject has a viable singleton or twin pregnancy;
* 3\. Subject is confirmed to be at least 10 weeks, 0 days gestation at the time of the study blood draw;
* 4\. Subject is planning to undergo CVS and/or amniocentesis for the purpose of genetic analysis of the fetus OR the subject has already undergone CVS and/or amniocentesis and is known to have a fetus with a chromosomal abnormality confirmed by genetic analysis.
Exclusion Criteria:
* 1\. Subject has known aneuploidy;
* 2\. Subject is pregnant with more than two fetuses or has had sonographic evidence of three or more gestational sacs at any time during pregnancy;
* 3\. Subject has a fetal demise (including natural or elective reduction) identified prior to consent;
* 4\. Subject has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant;